Detalles de la búsqueda
1.
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
J Transl Med
; 20(1): 159, 2022 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35382857
2.
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Breast Cancer Res
; 23(1): 38, 2021 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33761970
3.
Feasibility and Predictive Performance of a Triage System for Patients with Cancer During the COVID-19 Pandemic.
Oncologist
; 26(4): e694-e703, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33539583
4.
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
Breast Cancer Res
; 22(1): 83, 2020 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32758299
5.
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study.
Future Oncol
; 16(27): 2059-2073, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32598185
6.
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
Breast Cancer Res
; 21(1): 71, 2019 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31142370
7.
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.
Future Oncol
; 14(9): 849-859, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29527957
8.
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Oncologist
; 22(6): 648-654, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28432226
9.
Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?
Oncologist
; 20(7): 719-24, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26018662
10.
Measures of outcome in metastatic breast cancer: insights from a real-world scenario.
Oncologist
; 19(6): 608-15, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24794159
11.
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial.
JCO Precis Oncol
; 8: e2300285, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38427931
12.
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Nat Commun
; 15(1): 146, 2024 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38167503
13.
Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.
Melanoma Res
; 33(5): 398-405, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37402350
14.
Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib.
Tumori
; 109(6): 537-545, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37417313
15.
The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study.
Cancers (Basel)
; 15(7)2023 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37046641
16.
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.
Clin Cancer Res
; 29(1): 67-80, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36165912
17.
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
J Clin Oncol
; 41(2): 212-221, 2023 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36049147
18.
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
Breast Cancer Res Treat
; 134(1): 283-9, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22476856
19.
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy.
Anticancer Drugs
; 23(3): 326-34, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22129512
20.
CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature.
Curr Oncol
; 29(12): 9630-9639, 2022 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36547170